Idexx Laboratories (IDXX) Cash & Equivalents (2009 - 2026)

Idexx Laboratories' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $200.5 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 22.3% year-over-year to $200.5 million; the TTM figure through Mar 2026 stood at $200.5 million (up 22.3% YoY), while the FY2025 annual figure was $180.1 million, down 37.53% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $200.5 million, up from $180.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $453.9 million in Q4 2023, with the low at $99.2 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $200.5 million (2026), against an average of $227.9 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents surged 303.33% in 2023, then sank 59.01% in 2025.
• Idexx Laboratories' Cash & Equivalents stood at $112.5 million in 2022, then jumped by 303.33% to $453.9 million in 2023, then slumped by 36.5% to $288.3 million in 2024, then plunged by 37.53% to $180.1 million in 2025, then grew by 11.36% to $200.5 million in 2026.
• Business Quant data shows IDXX's Cash & Equivalents at $200.5 million in Q1 2026, $180.1 million in Q4 2025, and $208.2 million in Q3 2025.